S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:LHCG

LHC Group Competitors

$210.62
-0.93 (-0.44 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$209.55
Now: $210.62
$214.27
50-Day Range
$195.65
MA: $210.03
$221.64
52-Week Range
$100.00
Now: $210.62
$236.81
Volume135,913 shs
Average Volume162,631 shs
Market Capitalization$6.65 billion
P/E Ratio64.02
Dividend YieldN/A
Beta0.46

Competitors

LHC Group (NASDAQ:LHCG) Vs. LH, DGX, DVA, AMED, CHE, and AMN

Should you be buying LHCG stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to LHC Group, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), and AMN Healthcare Services (AMN).

Laboratory Co. of America (NYSE:LH) and LHC Group (NASDAQ:LHCG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Institutional and Insider Ownership

89.3% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 91.8% of LHC Group shares are owned by institutional investors. 0.7% of Laboratory Co. of America shares are owned by company insiders. Comparatively, 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Laboratory Co. of America and LHC Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011502.94
LHC Group02602.75

Laboratory Co. of America presently has a consensus price target of $226.8235, indicating a potential upside of 1.39%. LHC Group has a consensus price target of $205.5556, indicating a potential downside of 2.40%. Given Laboratory Co. of America's stronger consensus rating and higher possible upside, equities analysts clearly believe Laboratory Co. of America is more favorable than LHC Group.

Profitability

This table compares Laboratory Co. of America and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America6.79%21.05%8.83%
LHC Group5.00%9.71%6.51%

Earnings and Valuation

This table compares Laboratory Co. of America and LHC Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion1.89$823.80 million$11.3219.76
LHC Group$2.08 billion3.20$95.73 million$4.4747.12

Laboratory Co. of America has higher revenue and earnings than LHC Group. Laboratory Co. of America is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Laboratory Co. of America has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Summary

Laboratory Co. of America beats LHC Group on 10 of the 14 factors compared between the two stocks.

Quest Diagnostics (NYSE:DGX) and LHC Group (NASDAQ:LHCG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Institutional and Insider Ownership

85.7% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 91.8% of LHC Group shares are owned by institutional investors. 1.5% of Quest Diagnostics shares are owned by company insiders. Comparatively, 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Quest Diagnostics and LHC Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest Diagnostics010702.41
LHC Group02602.75

Quest Diagnostics presently has a consensus price target of $126.6471, indicating a potential upside of 1.81%. LHC Group has a consensus price target of $205.5556, indicating a potential downside of 2.40%. Given Quest Diagnostics' higher possible upside, equities analysts clearly believe Quest Diagnostics is more favorable than LHC Group.

Profitability

This table compares Quest Diagnostics and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest Diagnostics13.22%19.23%8.77%
LHC Group5.00%9.71%6.51%

Earnings and Valuation

This table compares Quest Diagnostics and LHC Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest Diagnostics$7.73 billion2.17$858 million$6.5618.96
LHC Group$2.08 billion3.20$95.73 million$4.4747.12

Quest Diagnostics has higher revenue and earnings than LHC Group. Quest Diagnostics is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Quest Diagnostics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Summary

Quest Diagnostics beats LHC Group on 9 of the 14 factors compared between the two stocks.

DaVita (NYSE:DVA) and LHC Group (NASDAQ:LHCG) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for DaVita and LHC Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita04202.33
LHC Group02602.75

DaVita presently has a consensus price target of $116.40, indicating a potential downside of 1.98%. LHC Group has a consensus price target of $205.5556, indicating a potential downside of 2.40%. Given DaVita's higher probable upside, research analysts plainly believe DaVita is more favorable than LHC Group.

Institutional & Insider Ownership

91.7% of DaVita shares are owned by institutional investors. Comparatively, 91.8% of LHC Group shares are owned by institutional investors. 1.0% of DaVita shares are owned by company insiders. Comparatively, 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

DaVita has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Profitability

This table compares DaVita and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.32%43.99%5.27%
LHC Group5.00%9.71%6.51%

Valuation and Earnings

This table compares DaVita and LHC Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion1.17$810.98 million$5.4021.99
LHC Group$2.08 billion3.20$95.73 million$4.4747.12

DaVita has higher revenue and earnings than LHC Group. DaVita is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Amedisys (NASDAQ:AMED) and LHC Group (NASDAQ:LHCG) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Amedisys and LHC Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys03902.75
LHC Group02602.75

Amedisys presently has a consensus price target of $263.6923, indicating a potential downside of 10.28%. LHC Group has a consensus price target of $205.5556, indicating a potential downside of 2.40%. Given LHC Group's higher probable upside, analysts plainly believe LHC Group is more favorable than Amedisys.

Institutional & Insider Ownership

85.9% of Amedisys shares are owned by institutional investors. Comparatively, 91.8% of LHC Group shares are owned by institutional investors. 2.8% of Amedisys shares are owned by company insiders. Comparatively, 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Amedisys has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Profitability

This table compares Amedisys and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys8.22%26.41%12.43%
LHC Group5.00%9.71%6.51%

Valuation and Earnings

This table compares Amedisys and LHC Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion4.93$126.83 million$4.4066.79
LHC Group$2.08 billion3.20$95.73 million$4.4747.12

Amedisys has higher earnings, but lower revenue than LHC Group. LHC Group is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Summary

Amedisys beats LHC Group on 7 of the 13 factors compared between the two stocks.

Chemed (NYSE:CHE) and LHC Group (NASDAQ:LHCG) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for Chemed and LHC Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemed00203.00
LHC Group02602.75

Chemed presently has a consensus price target of $535.00, indicating a potential upside of 1.10%. LHC Group has a consensus price target of $205.5556, indicating a potential downside of 2.40%. Given Chemed's stronger consensus rating and higher probable upside, research analysts plainly believe Chemed is more favorable than LHC Group.

Institutional & Insider Ownership

86.0% of Chemed shares are owned by institutional investors. Comparatively, 91.8% of LHC Group shares are owned by institutional investors. 4.0% of Chemed shares are owned by company insiders. Comparatively, 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Chemed has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Profitability

This table compares Chemed and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemed13.11%38.13%21.70%
LHC Group5.00%9.71%6.51%

Valuation and Earnings

This table compares Chemed and LHC Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemed$1.94 billion4.35$219.92 million$13.9537.94
LHC Group$2.08 billion3.20$95.73 million$4.4747.12

Chemed has higher earnings, but lower revenue than LHC Group. Chemed is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Summary

Chemed beats LHC Group on 9 of the 14 factors compared between the two stocks.

AMN Healthcare Services (NYSE:AMN) and LHC Group (NASDAQ:LHCG) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings for AMN Healthcare Services and LHC Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AMN Healthcare Services00713.13
LHC Group02602.75

AMN Healthcare Services presently has a consensus price target of $70.8571, indicating a potential downside of 1.87%. LHC Group has a consensus price target of $205.5556, indicating a potential downside of 2.40%. Given AMN Healthcare Services' stronger consensus rating and higher probable upside, research analysts plainly believe AMN Healthcare Services is more favorable than LHC Group.

Valuation and Earnings

This table compares AMN Healthcare Services and LHC Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.22 billion1.53$113.99 million$3.1822.71
LHC Group$2.08 billion3.20$95.73 million$4.4747.12

AMN Healthcare Services has higher revenue and earnings than LHC Group. AMN Healthcare Services is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AMN Healthcare Services and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AMN Healthcare Services3.78%20.38%6.87%
LHC Group5.00%9.71%6.51%

Institutional & Insider Ownership

94.6% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 91.8% of LHC Group shares are owned by institutional investors. 1.4% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 4.8% of LHC Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

AMN Healthcare Services has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.

Summary

AMN Healthcare Services beats LHC Group on 10 of the 15 factors compared between the two stocks.


LHC Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.4$223.71-1.6%$21.79 billion$11.55 billion26.04Analyst Report
Increase in Short Interest
Quest Diagnostics logo
DGX
Quest Diagnostics
1.9$124.39-0.5%$16.76 billion$7.73 billion15.38
DaVita logo
DVA
DaVita
1.8$118.75-0.7%$13.30 billion$11.39 billion17.80Analyst Report
Increase in Short Interest
Amedisys logo
AMED
Amedisys
1.2$293.89-2.1%$9.64 billion$1.96 billion58.90Increase in Short Interest
Chemed logo
CHE
Chemed
2.0$529.20-1.4%$8.44 billion$1.94 billion32.09Decrease in Short Interest
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.2$72.21-0.3%$3.40 billion$2.22 billion38.62Analyst Revision
R1 RCM logo
RCM
R1 RCM
1.3$25.51-0.9%$2.98 billion$1.19 billion255.13Analyst Revision
Heavy News Reporting
The Providence Service logo
PRSC
The Providence Service
0.8$162.92-1.6%$2.31 billion$1.51 billion-2,714.88Increase in Short Interest
MEDNAX logo
MD
MEDNAX
1.4$23.60-1.3%$2.02 billion$3.51 billion-2.73Increase in Short Interest
Heavy News Reporting
CorVel logo
CRVL
CorVel
0.8$105.51-0.1%$1.89 billion$592.22 million46.89
Tivity Health logo
TVTY
Tivity Health
1.6$20.65-2.5%$1.00 billion$1.13 billion-2.09Analyst Downgrade
Heavy News Reporting
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.1$9.11-0.9%$342.20 million$822.22 million-17.52Increase in Short Interest
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.6$4.10-1.7%$16.57 million$24.08 million-0.48Decrease in Short Interest
Heavy News Reporting
This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.